Literature DB >> 8906545

N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues.

T Sugiura1, S Kondo, A Sukagawa, T Tonegawa, S Nakane, A Yamashita, K Waku.   

Abstract

The effects of N-arachidonoylethanolamine (anandamide) and related compounds on the binding of [3H]CP55940 to rat brain synaptosomes were examined. Anandamide was shown to inhibit competitively the specific binding of [3H]CP55940 to synaptosomal membranes. The Ki value was 89 nM. In contrast, N-acylethanolamines containing saturated or monoenoic fatty acids did not exhibit high binding affinity. Several structural analogues of anandamide showed some binding activity. Among them, 2-arachidonoylglycerol is noteworthy because of its occurrence in mammalian tissues. A biosynthetic study indicated that anandamide can be synthesized via two separate synthetic pathways. The first is synthesis from free arachidonic acid and ethanolamine, and the second is the formation of N-arachidonoyl phosphatidylethanolamine (PE) from diarachidonoyl phospholipids and PE and the subsequent enzymatic release of N-arachidonoylethanolamine. The latter pathway appears to explain very well the fatty acid composition of N-acylethanolamines present in mammalian tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906545     DOI: 10.1016/0929-7855(96)00508-1

Source DB:  PubMed          Journal:  J Lipid Mediat Cell Signal        ISSN: 0929-7855


  9 in total

1.  Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets.

Authors:  A Berger; G Crozier; T Bisogno; P Cavaliere; S Innis; V Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Constitutive Increases in Amygdalar Corticotropin-Releasing Factor and Fatty Acid Amide Hydrolase Drive an Anxious Phenotype.

Authors:  Luis A Natividad; Matthew W Buczynski; Melissa A Herman; Dean Kirson; Christopher S Oleata; Cristina Irimia; Ilham Polis; Roberto Ciccocioppo; Marisa Roberto; Loren H Parsons
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

Review 3.  Therapeutic potential of cannabinoids in CNS disease.

Authors:  J Ludovic Croxford
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  The therapeutic potential of novel cannabinoid receptors.

Authors:  Faith R Kreitzer; Nephi Stella
Journal:  Pharmacol Ther       Date:  2009-02-25       Impact factor: 12.310

5.  Phosphatidylinositol-4-phosphate 5-kinase isoforms exhibit acyl chain selectivity for both substrate and lipid activator.

Authors:  Yulia V Shulga; Richard A Anderson; Matthew K Topham; Richard M Epand
Journal:  J Biol Chem       Date:  2012-09-01       Impact factor: 5.157

6.  Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.

Authors:  Balapal S Basavarajappa
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

7.  Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats.

Authors:  Zoltán Hegyi; Krisztina Holló; Gréta Kis; Ken Mackie; Miklós Antal
Journal:  Glia       Date:  2012-05-09       Impact factor: 7.452

Review 8.  Critical enzymes involved in endocannabinoid metabolism.

Authors:  Balapal S Basavarajappa
Journal:  Protein Pept Lett       Date:  2007       Impact factor: 1.890

Review 9.  Coenzyme-A-Independent Transacylation System; Possible Involvement of Phospholipase A2 in Transacylation.

Authors:  Atsushi Yamashita; Yasuhiro Hayashi; Naoki Matsumoto; Yoko Nemoto-Sasaki; Takanori Koizumi; Yusuke Inagaki; Saori Oka; Takashi Tanikawa; Takayuki Sugiura
Journal:  Biology (Basel)       Date:  2017-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.